Your browser doesn't support javascript.
loading
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Grosicki, Sebastian; Simonova, Maryana; Spicka, Ivan; Pour, Ludek; Kriachok, Iryrna; Gavriatopoulou, Maria; Pylypenko, Halyna; Auner, Holger W; Leleu, Xavier; Doronin, Vadim; Usenko, Ganna; Bahlis, Nizar J; Hajek, Roman; Benjamin, Reuben; Dolai, Tuphan K; Sinha, Dinesh K; Venner, Christopher P; Garg, Mamta; Gironella, Mercedes; Jurczyszyn, Artur; Robak, Pawel; Galli, Monica; Wallington-Beddoe, Craig; Radinoff, Atanas; Salogub, Galina; Stevens, Don A; Basu, Supratik; Liberati, Anna M; Quach, Hang; Goranova-Marinova, Vesselina S; Bila, Jelena; Katodritou, Eirini; Oliynyk, Hanna; Korenkova, Sybiryna; Kumar, Jeevan; Jagannath, Sundar; Moreau, Phillipe; Levy, Moshe; White, Darrell; Gatt, Moshe E; Facon, Thierry; Mateos, Maria V; Cavo, Michele; Reece, Donna; Anderson, Larry D; Saint-Martin, Jean-Richard; Jeha, Jacqueline; Joshi, Anita A; Chai, Yi; Li, Lingling.
Afiliación
  • Grosicki S; Medical University of Silesia, Katowice, Poland. Electronic address: sgrosicki@wp.pl.
  • Simonova M; Institute of Blood Pathology and Transfusion Medicine, National Academy of Medical Sciences of Ukraine, Lviv, Ukraine.
  • Spicka I; Charles University and General Hospital, Prague, Czech Republic.
  • Pour L; Clinic of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
  • Kriachok I; National Cancer Institute Ukraine, Kiev, Ukraine.
  • Gavriatopoulou M; Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Pylypenko H; Department of Hematology, Cherkassy Regional Oncological Center, Cherkassy, Ukraine.
  • Auner HW; Imperial College London, London, UK.
  • Leleu X; Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France.
  • Doronin V; City Clinical Hospital No. 40, Moscow, Russia.
  • Usenko G; City Clinical Hospital 4 of Dnipro City Council, City Hematology Center, Dnipro, Ukraine.
  • Bahlis NJ; Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada.
  • Hajek R; Department of Hemato-oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Benjamin R; Kings College NHS Foundation Trust, Kings College London, London, UK.
  • Dolai TK; Nil Ratan Sircar Medical College and Hospital, Kolkata, India.
  • Sinha DK; State Cancer Institute, Indira Gandhi Institute of Medical Sciences, Patna, India.
  • Venner CP; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
  • Garg M; University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Gironella M; Vall d'Hebron University Hospital, Barcelona, Spain.
  • Jurczyszyn A; Department of Hematology, Jagiellonian University Medical College, Kraków, Poland.
  • Robak P; Department of Hematology, Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland.
  • Galli M; Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Wallington-Beddoe C; Flinders Medical Centre and Flinders University, Adelaide, SA, Australia.
  • Radinoff A; University Hospital "St Ivan Rilski" EAD, Sofia, Bulgaria.
  • Salogub G; Chemotherapy of Oncology Diseases-Bone Marrow Transplantation Department 1, Almazov National Medical Research Centre, Ministry of Health of Russia, St Petersburg, Russia.
  • Stevens DA; Norton Cancer Institute, St Matthews Campus, Louisville, KY, USA.
  • Basu S; New Cross Hospital, Royal Wolverhampton NHS Trust and University of Wolverhampton, Wolverhampton, UK.
  • Liberati AM; Oncohematology Hospital S Maria Terni, University of Perugia, Terni, Italy.
  • Quach H; University of Melbourne, St Vincent's Hospital, Melbourne, VIC, Australia.
  • Goranova-Marinova VS; University Hospital "Sv Georgi" EAD, Clinic of Clinical Hematology, Medical University of Plovdiv, Plovdiv, Bulgaria.
  • Bila J; Clinic for Hematology, Clinical Centre of Serbia, Belgrade, Serbia.
  • Katodritou E; Hematology Department, Theagenion Cancer Hospital, Thessaloniki, Greece.
  • Oliynyk H; Department of Hematology, Vinnytsia M I Pyrohov Regional Clinical Hospital, Vinnytsia, Ukraine.
  • Korenkova S; Bone Marrow Transplantation Department, Kyiv Bone Marrow Transplantation Center, Kyiv, Ukraine.
  • Kumar J; Tata Medical Center, Kolkata, India.
  • Jagannath S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Moreau P; University Hospital, Hotel-Dieu, Nantes, France.
  • Levy M; Baylor University Medical Center, Dallas, TX, USA.
  • White D; Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada.
  • Gatt ME; Hadassah Hebrew University Medical Center, Jerusalem, Israel.
  • Facon T; CHU Lille Service des Maladies du Sang F-59000, Lille, France.
  • Mateos MV; Hospital Universitario de Salamanca, Salamanca, Spain.
  • Cavo M; Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Istituto di Ematologia "Seràgnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy.
  • Reece D; University Health Network-Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Anderson LD; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Saint-Martin JR; Karyopharm Therapeutics, Newton, MA, USA.
  • Jeha J; Karyopharm Therapeutics, Newton, MA, USA.
  • Joshi AA; Karyopharm Therapeutics, Newton, MA, USA.
  • Chai Y; Karyopharm Therapeutics, Newton, MA, USA.
  • Li L; Karyopharm Therapeutics, Newton, MA, USA.
Lancet ; 396(10262): 1563-1573, 2020 11 14.
Article en En | MEDLINE | ID: mdl-33189178
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Triazoles / Dexametasona / Bortezomib / Hidrazinas / Mieloma Múltiple / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Triazoles / Dexametasona / Bortezomib / Hidrazinas / Mieloma Múltiple / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Año: 2020 Tipo del documento: Article